- Home
- IBRX vs EVTC Comparison
IBRX vs EVTC Comparison
Compare IBRX & EVTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- EVTC
- Stock Information
- Founded
- IBRX 2014
- EVTC 1988
- Country
- IBRX United States
- EVTC United States
- Employees
- IBRX N/A
- EVTC N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- EVTC EDP Services
- Sector
- IBRX Health Care
- EVTC Technology
- Exchange
- IBRX Nasdaq
- EVTC Nasdaq
- Market Cap
- IBRX 2.4B
- EVTC 2.1B
- IPO Year
- IBRX N/A
- EVTC 2013
- Fundamental
- Price
- IBRX $4.49
- EVTC $34.64
- Analyst Decision
- IBRX Buy
- EVTC Hold
- Analyst Count
- IBRX 2
- EVTC 3
- Target Price
- IBRX $17.38
- EVTC $34.33
- AVG Volume (30 Days)
- IBRX 10.4M
- EVTC 369.1K
- Earning Date
- IBRX 11-12-2024
- EVTC 11-06-2024
- Dividend Yield
- IBRX N/A
- EVTC 0.58%
- EPS Growth
- IBRX N/A
- EVTC N/A
- EPS
- IBRX N/A
- EVTC 1.28
- Revenue
- IBRX $7,332,000.00
- EVTC $823,712,000.00
- Revenue This Year
- IBRX $1,563.18
- EVTC $24.29
- Revenue Next Year
- IBRX $1,262.20
- EVTC $6.76
- P/E Ratio
- IBRX N/A
- EVTC $27.08
- Revenue Growth
- IBRX 1218.71
- EVTC 24.45
- 52 Week Low
- IBRX $3.10
- EVTC $28.76
- 52 Week High
- IBRX $10.53
- EVTC $42.21
- Technical
- Relative Strength Index (RSI)
- IBRX 46.07
- EVTC 56.76
- Support Level
- IBRX $4.57
- EVTC $34.19
- Resistance Level
- IBRX $5.08
- EVTC $36.24
- Average True Range (ATR)
- IBRX 0.54
- EVTC 0.81
- MACD
- IBRX -0.12
- EVTC 0.18
- Stochastic Oscillator
- IBRX 3.16
- EVTC 62.09
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
About EVTC Evertec Inc.
Evertec Inc is a transaction processing business in Latin America and the Caribbean. Its business segments are Merchant Acquiring, Payment Services - Puerto Rico & Caribbean, Latin America Payments and Solutions, and Business Solutions which derive maximum revenue. The company serves a diversified customer base of financial institutions, merchants, corporations, and government agencies with mission-critical technology solutions that enable them to issue, process, and accept transactions securely.